DIANTHUS THERAPEUTICS INC (DNTH) Stock Income Statement
NASDAQ:DNTH - Nasdaq - US2528281080 - Common Stock - Currency: USD
| TTM (2025-3-31) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 6.52M | 6.24M | 2.83M | 0.00 | 0.00 | |||
| Operating Expenses | 123.72M | 108.10M | 51.00M | 80.90M | 74.69M | |||
| Research and Development | 96.96M | 83.05M | 32.84M | 55.14M | 46.77M | |||
| Selling, General, and Administrative Expenses | 26.76M | 25.05M | 18.16M | 25.76M | 27.93M | |||
| Operating Income | -117.20M | -101.86M | -48.17M | -80.90M | -74.69M | |||
| Interest Income/Expense | 17.00M | 17.45M | 4.68M | 4.44M | 3.56M | |||
| Other Income/Expense | -538.00K | -554.00K | -60.00K | N/A | N/A | |||
| Income Before Taxes | -100.73M | -84.97M | -43.55M | -76.46M | -71.14M | |||
| Income Tax | N/A | N/A | N/A | N/A | N/A | |||
| Net Income | -100.73M | -84.97M | -43.55M | -76.46M | -71.14M | |||
| EBITDA | -117.10M | -101.77M | -48.11M | -78.97M | -72.67M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -2.88 | -2.55 | -8.45 | -20.61 | -20.74 | |||
| Non GAAP EPS | -2.88 | -2.60 | -12.97 | -20.64 | -1.31 | |||
| Statistics | ||||||||
| Profit Margin | -1544.02% | -1362.77% | -1541.22% | N/A | N/A | |||
| Operating Profit Margin | -1796.40% | -1633.74% | -1704.67% | N/A | N/A | |||
All data in USD